Reproductive issues in women on direct oral anticoagulants
Abstract Direct oral anticoagulants (DOACs) are replacing warfarin and other vitamin K antagonists for a wide range of indications. Advantages of DOAC therapy are fewer food and drug interactions and fixed dosing without routine laboratory monitoring, making DOACs the perfect choice especially for y...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-05-01
|
| Series: | Research and Practice in Thrombosis and Haemostasis |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/rth2.12512 |
| _version_ | 1797707725691420672 |
|---|---|
| author | Jan Beyer‐Westendorf Sandra Marten |
| author_facet | Jan Beyer‐Westendorf Sandra Marten |
| author_sort | Jan Beyer‐Westendorf |
| collection | DOAJ |
| description | Abstract Direct oral anticoagulants (DOACs) are replacing warfarin and other vitamin K antagonists for a wide range of indications. Advantages of DOAC therapy are fewer food and drug interactions and fixed dosing without routine laboratory monitoring, making DOACs the perfect choice especially for younger patients, in whom the main indication for anticoagulation is prevention and treatment of venous thromboembolism (VTE). Although DOACs are safer and much more convenient than other anticoagulant alternatives, their profile may have drawbacks, especially for younger female patients in whom reproductive issues need special considerations. These may include the issue of heavy menstrual bleeding (HMB) during anticoagulant therapy, the embryotoxicity risk from inadvertent DOAC exposure during pregnancy, and the prevention or planning of pregnancies during DOAC therapy. This review summarizes the most relevant evidence in this increasingly important field of women’s health. |
| first_indexed | 2024-03-12T06:11:40Z |
| format | Article |
| id | doaj.art-68637a64a06743418516ec6d75ff763e |
| institution | Directory Open Access Journal |
| issn | 2475-0379 |
| language | English |
| last_indexed | 2024-03-12T06:11:40Z |
| publishDate | 2021-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Research and Practice in Thrombosis and Haemostasis |
| spelling | doaj.art-68637a64a06743418516ec6d75ff763e2023-09-03T02:56:59ZengElsevierResearch and Practice in Thrombosis and Haemostasis2475-03792021-05-0154n/an/a10.1002/rth2.12512Reproductive issues in women on direct oral anticoagulantsJan Beyer‐Westendorf0Sandra Marten1Thrombosis Research Unit Department of Medicine I Division Haematology University Hospital “Carl Gustav Carus” Dresden Dresden GermanyThrombosis Research Unit Department of Medicine I Division Haematology University Hospital “Carl Gustav Carus” Dresden Dresden GermanyAbstract Direct oral anticoagulants (DOACs) are replacing warfarin and other vitamin K antagonists for a wide range of indications. Advantages of DOAC therapy are fewer food and drug interactions and fixed dosing without routine laboratory monitoring, making DOACs the perfect choice especially for younger patients, in whom the main indication for anticoagulation is prevention and treatment of venous thromboembolism (VTE). Although DOACs are safer and much more convenient than other anticoagulant alternatives, their profile may have drawbacks, especially for younger female patients in whom reproductive issues need special considerations. These may include the issue of heavy menstrual bleeding (HMB) during anticoagulant therapy, the embryotoxicity risk from inadvertent DOAC exposure during pregnancy, and the prevention or planning of pregnancies during DOAC therapy. This review summarizes the most relevant evidence in this increasingly important field of women’s health.https://doi.org/10.1002/rth2.12512direct oral anticoagulantsDOACembryotoxicityheavy menstrual bleedingHMBpregnancy |
| spellingShingle | Jan Beyer‐Westendorf Sandra Marten Reproductive issues in women on direct oral anticoagulants Research and Practice in Thrombosis and Haemostasis direct oral anticoagulants DOAC embryotoxicity heavy menstrual bleeding HMB pregnancy |
| title | Reproductive issues in women on direct oral anticoagulants |
| title_full | Reproductive issues in women on direct oral anticoagulants |
| title_fullStr | Reproductive issues in women on direct oral anticoagulants |
| title_full_unstemmed | Reproductive issues in women on direct oral anticoagulants |
| title_short | Reproductive issues in women on direct oral anticoagulants |
| title_sort | reproductive issues in women on direct oral anticoagulants |
| topic | direct oral anticoagulants DOAC embryotoxicity heavy menstrual bleeding HMB pregnancy |
| url | https://doi.org/10.1002/rth2.12512 |
| work_keys_str_mv | AT janbeyerwestendorf reproductiveissuesinwomenondirectoralanticoagulants AT sandramarten reproductiveissuesinwomenondirectoralanticoagulants |